Stevanato Group S.p.A. (87N.F)
| Previous close | 24.00 |
| Open | 24.20 |
| Bid | 24.00 x N/A |
| Ask | 24.80 x N/A |
| Day's range | 23.80 - 24.40 |
| 52-week range | 22.00 - 32.60 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 6.78B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 44.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.05 (0.23%) |
| Ex-dividend date | 07 June 2023 |
| 1y target est | N/A |
- Business Wire
Stevanato Group to Present at the Bank of America Securities Healthcare Conference
PIOMBINO DESE, Italy, May 01, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.
- Business Wire
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
PIOMBINO DESE, Italy, April 25, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
- Business Wire
Stevanato Group appoints Ugo Gay as Chief Operations Officer
PIOMBINO DESE, Italy, April 04, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
